Rectal Cancer

P=N/A, N=50, Recruiting, Centre Paul Strauss | Trial completion date: Sep 2026 --> Jul 2030

In colon cancer, the adverse prognostic signal within T4N0 disease appears to be driven primarily by T4bN0. These findings support reconsideration of current staging paradigms, particularly for T4bN0 colon cancer, and warrant further prospective validation of risk-adapted postoperative strategies.

We present a 57-year-old man with KRAS G13D-mutant, liver-dominant metastatic rectal adenocarcinoma and recurrent fluoropyrimidine-associated coronary vasospasm precluding 5-fluorouracil and capecitabine. After multimodal first-line therapy and regorafenib, trifluridine/tipiracil (TAS-102) plus bevacizumab was initiated and integrated with liver-directed treatments for oligoprogressive disease. This combined strategy achieved approximately 16.6 months of disease control, substantially exceeding the median progression-free survival reported in the SUNLIGHT trial, with manageable hematological toxicity and preserved performance status. This case highlights the value of TAS-102 plus bevacizumab combined with focal liver-directed therapy as a feasible long-term strategy for selected patients with oligoprogressive mCRC when fluoropyrimidines cannot be used.

P=N/A, N=216, Recruiting, Sun Yat-sen University

The minimally invasive anatomical approach allowed precise vascular control and achievement of oncologically adequate margins in a technically demanding central segment. Larger clinical series are needed to define optimal management strategies and long-term oncologic outcomes in this setting.

P2, N=10, Not yet recruiting, Dr. Te Vuong

P=N/A, N=2, Terminated, Massachusetts General Hospital | Phase classification: P2 --> P=N/A

We discuss how lipid metabolism, iron homeostasis, cysteine-dependent antioxidant systems, and immune signaling pathways converge to regulate ferroptotic vulnerability and radiation response. We further explore the therapeutic potential of integrating radiotherapy, ferroptosis-targeting strategies, and immunotherapy to overcome radioresistance and improve treatment outcomes in colorectal cancer.

In conclusion, the present study constructed and validated a prognostic model to predict OS and DFS in patients with stage II/III rectal cancer receiving NCRT, based on readily accessible clinical biomarkers. This model may have potential clinical utility for prognosis.

P1/2, N=178, Recruiting, Shenzhen Ionova Life Sciences Co., Ltd. | Not yet recruiting --> Recruiting

Changes in oral microbiota appeared less pronounced. These findings provide the biological context for understanding intestinal recovery after radiotherapy and indicate that more studies are needed to direct future efforts towards the peri-operative manipulation of gut microbiota.

P=N/A, N=100, Not yet recruiting, National Taiwan University Hospital